Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942095 · ClinicalTrials.gov registry record · Phase 1
Study of Ixazomib and Erlotinib in Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02942095: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02942095 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942095, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and commercially available to treat non-small cell lung cancer, but its use in advanced solid cancer is considered investigational. Ixazomib is FDA approved. The study doctor can explain how the study drugs are designed to work. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
- DRUG Erlotinib
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02942095
The ClinicalTrials.gov registry entry for NCT02942095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT02942095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02942095 about?
NCT02942095 is a clinical study titled "Study of Ixazomib and Erlotinib in Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and comme...
What is the current status of trial NCT02942095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-03-06. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT02942095?
The interventions under investigation include: Erlotinib (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02942095?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.